SiRNA targeting SHP-1 accelerates angiogenesis in a rat model of hindlimb ischemia

Atherosclerosis

Volumn 191, Issue 1, 2007, Pages 33-39

  Sugano, Masahiro ^a   Tsuchida, Keiko ^a   Maeda, Toyoki ^a   Makino, Naoki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Gene therapy; Hindlimb ischemia; Protein tyrosine phosphatase; SHP 1; siRNA

Indexed keywords

CYTOPLASM PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; SMALL INTERFERING RNA; TYROSINE; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CAPILLARY DENSITY; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HINDLIMB; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LIMB ISCHEMIA; MALE; NONHUMAN; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN RNA BINDING; PROTEIN TARGETING; RAT; RECEPTOR BINDING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE THERAPY; HUMANS; ISCHEMIA; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; RATS; RATS, WISTAR; RNA, SMALL INTERFERING; SHP1 PROTEIN TYROSINE PHOSPHATASE; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846860242     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.04.021     Document Type: Article

References (31)

1. Berkman R., Merrill M., and Reinhold W. Expression of the vascular permiability/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91 (1993) 153-159
2. Shweiki D., Itin A., Soffer D., and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845
3. Heldin C.H. Dimerization of cell surface receptors in signal transduction. Cell 80 (1995) 213-223
4. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., and Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol Chem 269 (1994) 26988-26995
5. Wo Y.Y., McCormack A.L., Shabanowitz J., et al. Sequencing, cloning, and expression of human red cell-type acid phosphatase, a cytoplasmic phosphotyrosyl protein phosphatase. J Biol Chem 267 (1992) 10856-10865
6. Plutzky J., Neel B.G., and Rosenberg R.D. Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci USA 89 (1992) 1123-1127
7. Chen H.E., Chang S., Trub T., and Neel B.G. Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol 16 (1996) 3685-3697
8. Klingmuller U., Lorenz U., Cantley L.C., Neel B.G., and Lodish H.F. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80 (1995) 729-738
9. Haque S.J., Harbor P., Tabrizi M., Yi T., and Williams B.R. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J Biol Chem 273 (1998) 33893-33896
10. Bousquet C., Delesque N., Lopez F., et al. sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1. J Biol Chem 273 (1998) 7099-7106
11. Guo D.Q., Wu L.W., Dunbar J.D., et al. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 275 (2000) 11216-11221
12. Nakagami H., Cui T.X., Iwai M., et al. Tumor necrosis factor-α inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells. Arteriorscler Throm Vasc Biol 22 (2002) 238-242
13. Sugano M., Tsuchida K., and Makino N. Intramuscular gene transfer of soluble TNF-α receptor 1 activates vascular endothelial growth factor receptor (KDR/flk-1) and accelerates angiogenesis in a rat model of hindlimb ischemia. Circulation 109 (2004) 797-802
14. Sugano M., Tsuchida K., Tomita H., and Makino N. Increased proliferation of endothelial cells with overexpression of soluble TNF-a receptor I gene. Atherosclerosis 162 (2002) 77-84
15. Wishcamper C.A., Brooks D.M., Douglas Coffin J., and Lurie D.I. Focal cerebral ischemia upregulates SHP-1 in reactive astrocytes in juvenile mice. Brain Res 974 (2003) 88-98
16. Brummelkamp T.R., Bernards R., and Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2 (2002) 243-247
17. Lewis D.L., Hagstrom J.E., Loomis A.G., Wolff J.A., and Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 32 (2002) 107-108
18. McCaffrey A.P., Meuse L., Pham T.T., Conklin D.S., Hannon G.J., and Kay M.A. RNA interference in adult mice. Nature 418 (2002) 38-39
19. Takeshita S., Isshiki T., and Sato T. Increased expression of direct gene transfer into skeletal muscles observed after acute ischemic injury in rats. Lab Invest 74 (1996) 1061-1065
20. Tsurumi Y., Kearney M., Chen D., et al. Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation 96 Suppl II (1997) II382-II388
21. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., and Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255 (1992) 989-991
22. Terman B.I., Dougher-Vermazen M., Carrion M.E., et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187 (1992) 1579-1586
23. Millauer B., Wizigmann-Voos S., Schnurch H., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72 (1993) 835-846
24. Shalaby F., Rossant J., Yamaguchi T.P., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376 (1995) 62-66
25. Fong G.H., Rossant J., Gertsenstein, and Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376 (1995) 66-70
26. Hiratsuka S., Minowa O., Kuno J., Noda T., and Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95 (1998) 9349-9354
27. Wu L.W., Mayo L.D., Dunbar J.D., et al. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 275 (2000) 5096-5103
28. Kroll J., and Waltenberger J. A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem Biophys Res Commun 265 (1999) 636-639
29. Zhao Q., Egashira K., Inoue S., et al. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 105 (2002) 1110-1115
30. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., and Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7 (2001) 425-429
31. Dhawan S., Singh S., and Aggarwal B.B. Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol 27 (1997) 2172-2179